SAN DIEGO, Dec. 12, 2011 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that two doses of veltuzumab produced an overall objective response (OR) rate of 67%, including an 18% durable complete response (CR) rate, in 39 evaluable patients with immune thrombocytopenia (ITP). Responses occurred across all doses tested, including the lowest dose at 80 mg, regardless of the route of administration, history of splenectomy or prior use of rituximab.
